Search

canada - search results

If you're not happy with the results, please do another search

3 1708

The que to establish a Canadian legal marijuana business is getting unruly as applicants struggle to keep their dreams of selling med pot growing.

Written By: Matt Mernagh

This week licensed producer New Age Medical Solutions Inc. launched a lawsuit seeking a federal judge review their denial. http://www.cbc.ca/news/politics/medical-marijuana-applicant-takes-health-canada-to-court-1.2823362

 

The business waited a year and spent approximately one million dollars Canadian before Health Canada nixed their application. The company is part of a growing list of applicants who have spent a considerable sum and are in an approval quagmire.

 

Many are designated growers under the old program who have teamed up with investors and require to submit to extensive RCMP background checks. Long suspecting these growers are earning income from illegal sales – the RCMP is possibly using this as an opportunity to punish via slowness.

 

You’ll never prove beyond a shadow of a doubt they’re not moving paperwork quick enough because of political reasons, but they’re notoriously slow on regular background checks and blame staffing levels.

 

Having faced numerous constitutional challenges (including my own R v. Mernagh) – the agency responsible for overseeing licensed producers appears to have established their medical marijuana program with one eye on the courtroom.

Denied applicants may re-apply by fixing the identified problem – it’s alleged by Health Canada New Age Medical Solutions needs to hire a qualified quality assurance specialist.

 

Who is exactly qualified to be a quality assurance specialist for cannabis?

 

I have a book and held a court ordered exemption to grow cannabis – does that make me qualified.

 

A federal judge decision on that question could be years away and in the meantime the production facility sits empty.

 

Currently some 1,100 businesses have applied to sell medical marijuana to approximately 10,000 people. This number is growing as more doctors appear willing to sign paperwork. (I’m registered with Peace Naturals – which is not listed on TSX).

 

Health Canada claims about 291 businesses are in process of approval, but when will they be approved?

There’s a fairly impressive backlog of applicants and it includes a company headed by a former prime minister (John Turner) and another by a former Ontario provincial Liberal cabinet minister (George Smitherman.)

One would think a former prime minister would have some approval sway, but it doesn’t appear to be the case.

 

The snail’s pace approval is most likely somewhat intentional on government’s part. Unfortunately intentional government incompetence is a challenge to measure and if you’re one of 291 about to be approved – do you risk the agency’s ire by launching a lawsuit or speaking out.

 

To applicants and advocates it’s obvious pot hating Conservatives have slowed down the licensed producer application process to a God Bud couchlock.

 

Is this government incompetent business as usual or is an extra layer of personal dislike thrown in for good measure?

 

The Conservatives 2012 federal budget was described as “tough times for federal civil servants” with approximately 19,000 government employees given pink slips or retired out. The federal government shrank 4.8 percent and its effects are being felt everywhere, including medical marihuana approval.

 

Paper is not being pushed as quickly as applicants wish, probably because Health Canada doesn’t have adequate resources. Every business that qualifies will be granted a license, but Health Canada needs to have staff in place to manage all that Conservative created paperwork and oversight.

 

Will positive political muscle make a difference in moving paperwork?

 

The Mayor of Campbellton New Brunswick has come forward seeking the approval pace be quickened for Zenabis – which has promised a remarkable 400 weed jobs – when they open in his community. Campbellton’s been hard hit by unemployment and approximately 1400 people have applied for weed employment.

 

Is local Conservative MP Bernard Valcourt more interested in upholding prohibition or job creation?

It’s not uncommon for an MP to lobby on behalf of a business in their community that promises job creation – so why isn’t he going to bat for Zenabis?

The Conservative’s believe they are getting a two-for-one political ideological deal – smaller government and maintaining pot prohibition – but should be viewed as hampering job creation and investment.

Investors have tied up their cash flow in an investment that may or may not pay off. Many companies’ are bleeding money before they have even opened their doors. The approval uncertainty is finally causing investors to examine the possible payout more diligently.

Cannabis conspiracy theorist need look no further than Health Canada not having enough staff as to why more companies are not retailing medical cannabis than any other theory being floated.

 

0 538

Canada Will Tax Marijuana Just Like Tylenol

Cannabis Investment Expert Joins Supreme Pharmaceuticals

Supreme Pharma (SL-CSE) (SPRWF-OTCBB)

Interview with Brayden R. Sutton, Executive Vice President

VANCOUVER, British Columbia, Oct. 31, 2014 (GLOBE NEWSWIRE) — Tax Court Justice Campbell Miller just ruled that marijuana will be subject to federal Goods & Services Tax (GST) like Tylenol, cough drops and other over-the-counter drugs. The ruling confirms the government’s intent to legalise, regulate and tax medical marijuana in Canada. This is an important ruling, given that recent legislative changes have created a nascent medical marijuana industry in Canada that could be valued at over $1 Billion dollars in just a few years.

The creation of this newly commercialized industry creates a great opportunity for savvy investors to be early entrants and gain substantial returns. However, there are currently dozens of publically traded companies applying for permits to grow marijuana. The challenge is to pick the winning horse. With a space this cluttered it is instructive to see where the experts are placing their bets.

Supreme Pharmaceuticals (SL.V) (SPRWF) has just landed one of those experts, Mr. Brayden R. Sutton, President and CEO of CannabisHealth.com. Mr. Sutton joins Supreme as one of the most prominent cannabis investment experts in Canada, with nearly a decade spent covering the field from operational and public markets perspectives. As Executive Vice President of Supreme, Mr. Sutton will oversee facility design, operations, marketing, financing and business development.

“Being an early mover in the cannabis space, I was sought after and extended offers from almost every cannabis-related company in Western Canada as they all tried to position themselves in the marketplace,” stated Sutton in an exclusive interview with Financial Press, “Some of the offers were very tempting but I was truly looking for a company that checked all the boxes — the one that is providing Health Canada precisely what they’re looking for in the MMPR, one that could provide good value to their patients as well as their shareholders, and one that I felt will be around 10 years from now. I’m not interested in being a small player in the space or making a quick buck in a new sector – I want to take Supreme, the best company in the space in my opinion, to the finish line; and really set it up to be the dominant, low-cost, high-quality producer here in Canada.”

“Supreme received its ready-to-build permit back in January of this year,” stated Sutton, “Our facility has been fully retro-fitted to exceed the requirements of the Health Canada. It’s large, it’s secure, it’s in the right area, and we have local political support — on all levels. From local MP’s, the Mayor, and the town itself. We truly couldn’t be in a better town than Kincardine, Ontario. The 16-acre property, which houses the 7-acre facility, is located on the Bruce Energy Centre and has been independently appraised with an ‘in-use’ value of just under $22 million. We were fortunate enough to secure it for only $4.5m on very favourable terms. And frankly, we’ve yet to find a facility in Canada that is as more ideally suited to the MMPR as this one is, particularly when considering the local support, available skilled labour pool and heightened law enforcement presence due to our proximity to the Bruce Nuclear Power Plant. Our final phase of security is underway as we speak with Marcomm Systems Group and our Security Director, former OPP Drug Investigator Alan Roberton. We expect them to be complete by early November, at which point we will be ready to invite Health Canada to our facility for the inspection.”

Supreme’s Southern Ontario greenhouse is state-of-the-art, high tech facility utilizing advanced agricultural automation methods and applying them to the production of medical marijuana. It’s a 342,000 square foot greenhouse, which is the size of six NFL football fields. In addition, it is perfectly designed for medical marijuana production: it is built out of mould resistant tempered glass and steel, has sealed concrete flooring and is a “low top” design which reduces the facility’s heating and cooling requirements.

“We’ve employed Thaddeus Conrad, who is one of Canada’s leading producers of medical marijuana. Mr. Conrad is a leading breeder of innovative medical marijuana varieties, varieties which have earned him the title of North America’s most awarded marijuana breeder. As a result of this, Mr. Conrad is incredibly well-known under the name ‘Med-Man Brand,'” stated Sutton. “It is an honour to have him exclusively, as he brings with him decades of practical experience as well as a large and loyal patient following for early patient acquisition out of the gate. He is now collaborating with our team of greenhouse technicians, which includes one of Canada’s top agricultural experts who is a researcher at a well-known local University. At Supreme we have three elements: in our greenhouse we acquired the ideal facility, in Mr. Conrad we retained the best medical marijuana cultivator and breeder in the country and in our agricultural team we have some of the leading experts in pharmaceutical agricultural production. By doing this, we feel we will truly have the best value in the marketplace to offer our clients top-quality medicine, consistently, at a very affordable price.”

Sutton stresses that Supreme’s facility is far from a “grow-op” – it’s a high-tech pharmaceutical-grade greenhouse that is ideally suited for medical marijuana production. Health Canada has stated numerous times that it wants a regulated, standardized, automated production system that will turn out a consistent, and most importantly, safe product that meets their very stringent quality assurance measure, and we intend to give them just that. Supreme’s facility provides that; a large volume producer, with a design and operational plan designed for standardization and safety and sufficient economies of scale to implement robust quality control and quality assurance procedures. Supreme also benefits from favourable energy rates, due to the proximity of the local power plant, and most importantly the sun, which will provide up to 60% of the energy needed to produce high-quality medical marijuana.

Supreme is quickly checking off items required to be implemented prior to inspection: the razor-wire topped security fence is in place, the level-9 vault has been installed, the growing areas have been constructed and extensive electronic security and surveillance systems are being implemented right now. Once the final security systems are in place and the production areas are finalized, Supreme will be ready for its inspection by Health Canada. Mr. Sutton states that Supreme anticipates being ready for the inspection by mid November.

“What is unique about our greenhouse is that there is a large concrete structure in the center which houses the vault and high security processing areas. The greenhouse itself provides 4 quadrants of actual growing area, 340k sq. ft. in total, with our controlled rooms being 3,520 sq. ft. each. Even the flow of the building is ideal, in terms of the steps required from the trimming of the plant, to the shipping of it out the door. Employee and product flow has been meticulously designed to increase efficiency and reduce the risk of contamination. There will be an assembly line of sorts, where the production staff will be sealed off from the rest of the operation, allowing them to move the product down the line, while not interfering with anyone who is hands on inside of the actual grow space.”

Supreme Pharma has just raised $2.6M from a recent financing and currently undertaking an additional raise. And is more than capitalized to go right into production and start fulfilling patient orders.

Through economy of scale, Sutton anticipates drastically reducing the market price of cannabis.

“Our goal is to use the extensive medical marijuana expertise our management team has to shake up the marketplace. We will achieve this by using a gradient pricing model, which allows us to target multiple market segments while maintain transparency and credibility with our patients and doctors. We will sell the majority of our products for around $5.00 per gram. From there, premium parts of each crop will be given the ‘royal treatment’ and sold for upwards of $8.00 per gram, to those who can afford it. On the other end of the spectrum, smaller buds and shake will be sold for $2 and $1 respectively. Its all good medicine, but you have to be honest with the doctors and patients about what you are providing. The low cost options are also essential because a large proportion of our patients are very cost-sensitive, and currently expend a great deal of their monthly income on their medicine. The low cost model also improves our ability to pressure insurance providers to provide benefits for medical marijuana.”

Sutton is also very focused on patient acquisition, “The part of the business that many companies are struggling to find an effective way. We are very happy to say that we have roughly 500 patients on stand-by, with many more contacting us daily.” Mr. Sutton reports these patients come from existing relationships held by Supreme’s management team, as well as many individuals living or working near the facility, “and that has all been organic so far, as we’ve not yet had to pay one dime for patients. I have some long-standing relationships with cannabis-friendly physicians, and our hope is to be able to work closely with them, to better educate the public in what is very much going to be an industry driven part of Canada’s Health Care.” This is a benefit for Supreme, as this early patient acquisition is achieved without expending capital to acquire initial patients. In addition, Mr. Sutton reports that Supreme has had strong interest from a number of potential producers to provide marijuana on a wholesale basis. “This is the perfect market opportunity for Supreme, where we can supply others with wholesale marijuana and increase our revenues faster than we can acquire our own patients. Also, when you consider that less of an expense is required to sell wholesale medical marijuana as compared to retailing to individual patients, the profitability of our wholesale division is on par with the retail side.”

“We are in the final stages of completing of the requirements for our Southern Ontario growing facility,” stated Sutton, “I have a decade of experience in this field that tells me when something is going to work. Supreme Pharmaceuticals is that something. In my opinion, it is a question of ‘when’ not ‘if’ it becomes one of the dominant providers in this exciting new sector.”

Supreme Pharmaceuticals is currently trading at $.47 with a market cap of $28 million.

Legal Disclaimer/Disclosure: A fee has been paid for the production and distribution of this Report. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Financial Press makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the authors only and are subject to change without notice. Financial Press assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Also, please note that republishing of this article in its entirety is permitted as long as attribution and a back link to FinancialPress.com are provided. Thank you.

Contact:

Supreme Pharmaceuticals
Suite #430, 580 Hornby Street
Vancouver, BC
V6C 3B6
Email: info@supremepharmaceuticals.com
Phone: 604.674.2191

0 100

Enertopia Closes First Tranche of Financing

 Vancouver, BC / ACCESSWIRE / Jaunuary 30, 2015 / Enertopia Corporation (ENRT) on the OTCBB and (TOP) on the CSE (the “Company” or “Enertopia”) is pleased to announce it has closed the first tranche of CAD$99,900 for its Private Placement announced on November 5, 2014. Enertopia will be issuing 1,665,000 common shares at CAD$0.06 and 1,665,000 whole warrants that expire on January 30, 2018 with an exercise price of US$0.10 during the first 24 months and US$0.15 after 24 months until they expire on January 30, 2018.

A cash finder’s fee for $7,358.40 and 122,640 full broker warrants that expire on January 30, 2018 with the same exercise terms as noted above was paid to arm’s length party.

All issued shares will be subject to a hold period, for any resale into the United States under Rule 144, of six months and one day. Proceeds of the Private Placement will be used for general working capital, for corporate opportunities in the Medical Marihuana and health and wellness industries. The Private Placement will be subject to normal regulatory approvals.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President at 1.250.765.6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation of clean energy projects, oil & gas projects, , competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. There can be no assurance that the funds raised will have any positive impact on Enertopia. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

0 127

Easton Pharmaceuticals Discloses List of Joint Initiatives With Medicated Markets International LLC, Its California Based Medical Marijuana Partner

TORONTO, ON–(Marketwired – Jan 28, 2015) –  Easton Pharmaceuticals Inc. (OTC:EAPH) Announces list of joint initiatives with Medicated Markets International LLC, it’s California based medical marijuana partner.

Easton would like to provide further details and answers to questions posed to the company regarding current partnership aspirations shared with Medicated Markets International LLC, which includes expectations and future endeavours in both the US and Canadian medical marijuana markets.

Medicated Markets is currently narrowing down options for additional land purchases in Mendocino, California as well as Trinity County for an upgraded greenhouse facility build out. This joint venture initiative and land purchase timeline is set to complete sometime in the early spring.

Medicated Markets has also decided to enter the Toronto, Canada Medical Marijuana Market by setting up a dispensary location and allowing patients greater access to their medicinal needs. Medicated Markets has recently completed all preliminary due diligence on a dispensary and distribution site in Canada for Medical Marijuana. Currently Medicated Markets is actively searching for a retail location in the Greater Toronto Area. Co-distribution with current MMPR approved Health Canada Licensed Providers are in the initial stages of discussion but are fast moving and as such no additional details can be disclosed at this time.

Johnny Martinez, President of Medicated Markets, stated, “Our goals for this venture is much larger than joint dispensary locations in Toronto, Canada. We want to develop a topical patch and Gel delivery formulation to compete with other mouth spray type products currently available in the market as treatment. Topical Medical Marijuana for target site treatment of pain, skin and bone related medicinal use has been seen as an effective alternative to inhalation through the lungs.”

American Academy of Pediatrics (AAP) also recognized marijuana may be a treatment option for kids suffering with “life-limiting or severely debilitating conditions for whom current therapies are inadequate.” This pediatricians group will now suggest that the federal government change marijuana from a Schedule I illegal drug (where it’s classified alongside heroin) to a Schedule II controlled substance, Levy stated. The U.S. Drug Enforcement Administration lists Adderall or Ritalin as examples of Schedule II drugs. We now believe rescheduling of Medical marijuana is imminent in US jurisdictions.

On January 20th 2015 Easton Pharmaceuticals had announced a stock swap agreement with Medicated Markets International LLC and has allocated 200 Million restricted shares of Easton’s common stock to be held in escrow, as per agreement. In addition, payment of $100,000 has been wired to Medicated Markets and receipt of funds has been confirmed.

All responsibilities and liabilities with respect towards the medical marijuana business in California resides with Medicated Markets International. Easton is pleased and is confident it has partnered with knowledgeable and reputable company in Medicated Markets who share the same goal of moving the medical marijuana industry in both the United States and Canada successfully forward.

Medical cannabis is commonly used to self-treat, although not limited, severe pain associated with Cancer, arthritis, and musculoskeletal pain. As of June 2014, estimates from the office of Information Commissioner of Canada list “severe arthritis” as the reason that 65% of Canadians who are allowed to possess and use marijuana for medicinal purposes. Proposed initiative addresses site transmission of Transdermal marijuana extract to the site of the pain, without having to inhale through the lungs. Currently McGill University, McMaster University, and University of Guelph have research projects into Medical Marijuana in Canada.

The Medical Marijuana Movement in North America started in California, which was the first state to establish a medical marijuana program, enacted by Proposition 215 in 1996 and Senate Bill 420 in 2003. Prop. 215, also known as the Compassionate Use Act, was approved by an initiative with a 55% majority, allowing people with cancer, AIDS and other chronic illnesses the right to grow or obtain marijuana for medical purposes when recommended by a doctor. SB 420, or the Medical Marijuana Protection Act, was signed into law by Governor Gray Davis and established an identification card system for medical marijuana patients. Marijuana advocates are hopeful that if they can get a legalization measure on the ballot in California in 2016, it will pass and federal reform will follow shortly afterwards.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and other conditions that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has also received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

http://ecigmarkets.com/

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

0 91

Abattis Names William Fleming as CEO, Mike Withrow to Become International Business Lead

VANCOUVER, BRITISH COLUMBIA–(Marketwired – Jan 27, 2015) – Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK:ATTBF)(CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that William (Bill) Fleming, as Chief Executive Officer (CEO) of Abattis Bioceuticals Corp. effective February 1, 2015. He will succeed Mike Withrow, who is resigning his role as CEO and President to become International Business Advisor for Abattis and promote, develops, and manage opportunities for Abattis Bioceuticals Corp.

Mr. Fleming has founded and served as CEO for a number of entrepreneurial companies and has served with senior executive teams dealing with equity and debt financings. Mr. Fleming has developed corporate strategies for a wide range of companies, from family-owned businesses to multi-national companies. Mr. Fleming is a member of the Qalipu Mi’kmaq First Nation and has provided Advisory Consulting services to Health Canada under the Public Health Information Surveillance program. Mr. Fleming is the Founder of Mernova Medicinal Inc., an Aboriginal owned company focused on becoming a Canadian producer of legal marijuana. Mr. Fleming is a graduate of St. Francis Xavier University and a recipient of the Canadian Armed Forces ROTP Scholarship.

Mike Withrow will continue to serve as International Business Advisor for strategic development.

The board thanks Mr. Withrow for his vision in the founding and development of Abattis Bioceuticals Corp., and for the energy he has devoted to bringing the company to a leadership position in the field of botanical medicine analytics and production in the biotech sector. Mr. Withrow will, in his new role as International Business Advisor and strategic development, continue to seek out global opportunities for the expansion of the corporation’s activities.

Jaouad Fichtali was appointed in the role of Chief Technology Officer (CTO) of Abattis effective November 14, 2014, has resigning the position of CTO and will be assuming the role of Extraction Advisor effective immediately. This will allow the Company to conserve resources until the time when a CTO becomes vital.

Incentive Stock Options

The Company also announces that its Board of Directors has granted incentive stock options to purchase up to 175,000 common shares of the Company at a price of $0.16 per share for a period of five years to its directors, officers and consultants. The grant of stock options is subject to regulatory approval.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD

Bill Fleming, CEO

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

0 126

SinglePoint Announces Product Rollout, Tobacco, Vape Pen Distribution Strategy for Newly Acquired GreenStar Brand

SEATTLE, WA–(Marketwired – Jan 27, 2015) -SinglePoint Inc. (OTC: SING) announces that it will position its GreenStar brand to leverage new and existing relationships for a product rollout that will include both traditional and smokeless tobacco products ranging from electronic cigarettes, vape pens and, contingent on the trade embargo being lifted, Cuban cigars.

CEO Greg Lambrecht states,”I am very happy to have completed the GreenStar acquisition, and look forward to expanding into territory notably familiar to me while we continue harvesting opportunities and relationships in the legalized cannabis sector.”

As VP of Sales for Single-Stick, “PrimeTime,” a retail tobacco company, Mr. Lambrecht increased sales from $300,000 USD per year to $10 Million+ per year. SinglePoint execs agree, given Lambrecht’s experience in this realm, GreenStar is in a great position to capitalize on a trending market. As a reflection of its strategy for lateral expansion, GreenStar Payment Solutions, Inc. will now simply be branded as GreenStar.

Vape pens have grown in popularity over the past year to the extent that the Oxford dictionary chose “vape” as its 2014 word of the year. Use of the pens has more than doubled in the past twelve months.

SinglePoint has entered negotiations with Royale Tobacco regarding a vape pen distribution agreement with the option to develop a private label. Concurrently GreenStar is soliciting retail accounts to lay the foundation for placement candidates.

Finally, in preparation for possible changes in US – Cuba relations, SinglePoint CEO Greg Lambrecht has reached out to his long time cigar distribution partners and has presented a deal to distribute Cuban cigars in the US contingent on the potential for the trade embargo to be lifted. Mr. Lambrecht distributed cigars throughout the US and Canada. Mr. Lambrecht’s company Premium Cigars International (formerly PCI) had over 25,000 accounts. Mr. Lambrecht raised $10,000,000 through an IPO in 1997 as the founder and largest shareholder.

About GreenStar
GreenStar is a subsidiary of SinglePoint (OTC: SING). GreenStar focuses on providing a well developed distribution channel for retail and convenience store products in the tobacco and legalized cannabis sectors.

Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact:
Investor Relations
Greg Lambrecht
602-481-1544

0 232

Abattis alligns talent and Mike Withrow moves to  International Business Advisor

Vancouver, BC, / ACCESSWIRE / January 27, 2015 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that effective February 1st. Mike Withrow will move from his role as CEO and Chairman to a new position as International Business Advisor where he has identified opportunities in legal jurisdictions that are strategic to Abattis. The board is in discussions with its members and will be appointing a new CEO shortly. The CEO and Chairman positions will be filled with someone who has good relations with Health Canada and can been seen as a good partner by Health Canada.

The board thanks Mr. Withrow for his vision in the founding and development of Abattis Bioceuticals Corp., and for the energy he has devoted to bringing the company to a leadership position in the field of botanical medicine analytics and production in the biotech sector. Mr. Withrow will, in his new role as International Business Advisor he will continue to nurture strategic partnerships in select countries that enhance the corporation’s activities and maximize value of the Abattis technologies and assets.

Mr. Withrow was quoted as saying “As a significant shareholder of Abattis, I believe this is the best thing for the company as it moves through its next stage of growth. I look forward to bringing strategic international business partnerships to the company. Now is the time to bring in a CEO who has a proven track record in managing revenue and rapid growth.”

As we align our talent Jaouad Fichtali, who was appointed in the role of Chief Technology Officer (CTO) of Abattis effective November 14, 2014, will be assuming a more focused role as Advisor of Extraction IP effective immediately. This will allow the company to focus on and deploy its extraction technology with foreign partners.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD

“Mike Withrow”
Michael Withrow, President & CEO

For further information, contact IR for Abattis Bioceuticals Corp. at (604) or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

SOURCE: Abattis Bioceuticals Corp.

 

    0 660
    Marijuana Stocks

    By Juliette Fairley

    With experience in criminal defense, constitutional law, workplace drug policy and intellectual property, lawyers are at the forefront of the national movement to legalize marijuana. Here’s a list of five lawyers to watch in 2015 as legal medical and recreational marijuana continues to sweep the country.

    Douglas Sorocco -Educated as a biochemist, Douglas Sorocco practices intellectual property law related to cannabis technologies. “The cases I represent have to do with strains and chemical compounds that are being discovered and used for medicinal treatments,” said the Oklahoma based Sorocco. “We do the patent application and litigation for it.” The majority of Sorocco’s clients are pharmaceutical and life sciences companies from outside the U.S., such as Canada, the Netherlands and Uruguay. “The hot button issue is whether or not the federal government will allow patents on strains and if so what is going to be the amount of evidence or information they will require to grant those patents,” said Sorocco.

    Michael Minardi – Amendment 2 would have legalized marijuana for medical purposes in Florida had it passed on November 4 but it didn’t. As a result, Michael Minardi expects to continue to reduce the sentences of his marijuana using clients in West Palm Beach who are typically over 40 years old and suffer from conditions, such as AIDS, COPD, fibromyalgia and glaucoma. “The denial of Amendment 2 will not change my practice of defending patients who have been arrested for using cannabis as medicine and are presenting a medical necessity defense,” Minardi said. Minardi is also the legal director of the National Organization for the Reform of Marijuana Laws (NORML)

    Danielle Urban – Because impairment cannot be easily tested, employers worry that workers who use marijuana in their free time will harm themselves or others in the workplace, creating liability issues. However, zero tolerance corporate policies pose a special set of legal concerns. “Many employers are terrified they will be sued if they have zero tolerance policies and fire someone with a medical card,” said Urban, a labor and employment attorney in Colorado. “More research is needed to determine what constitutes impairment for work-safety purposes and the long-term health effects of marijuana use.” Urban said. Because drug policy varies from state to state, national employers are left with a patchwork of marijuana drug testing policies to figure out. “Some employers choose to stay out of their employees’ personal lives and have suspended testing because they don’t know what to do about marijuana use,” said Urban.

    Mara Felsen- Professional experience in constitutional, criminal and administrative law helped to create Mara Felsen’s unique legal perspective but it was a car accident that lead the San Diego attorney to turn her personal experiences as a medical marijuana patient into a cannabis law specialty.

    Robert Hoban – The Drug Enforcement Administration announced this month that it will not pursue for prosecution hemp based products with THC levels less than .3 percent. As a result, CBD and hemp attorney Robert Hoban predicts there will be a large push in the pot marketplace to develop methods to lower the THC content, which naturally rises during processing and purification process. “This will hedge any federal government interference even though the product is lawful and has higher levels of THC of .8 to 2.8%,” said the Denver-based Hoban who represents a number of the nation’s largest hemp and CBD importers, producers, processors and suppliers.

    0 168

    Easton Pharmaceuticals Inc Is Pleased to Announce Definitive Finalized Agreement With Medicated Markets International LLC, a Major California Based Medical Marijuana Grower

    TORONTO, ON–(Marketwired – Jan 20, 2015) – Easton Pharmaceuticals Inc. (OTC: EAPH) Signs Finalized agreement with Medicated Markets International LLC., a major California medical marijuana grower in a restricted share swap agreement. Up to 25% of Easton restricted stock, rights to use Easton’s transdermal matrix technologies, and One hundred thousand dollars; to be exchanged for 40% of Medicated Markets International LLC.

    Easton Pharmaceuticals has been searching to enter the highly Lucrative Medical Marijuana Grower market within legalized jurisdictions. Medicated Markets International LLC, is a current grower / cultivator located in the City of Perris, California, (20 acres) Riverside county and one main growing location in Mendocino County, California with a total actual growing area of approximately 3 acres. Medicated Markets has been looking to buy assets in Canada, including submission of their own MMPR application to Health Canada, or by buying a controlling interest in an already Licensed Provider. A growing US economy as well as strong Medical Marijuana demand In California, while Canadian assets have been falling has made this opportunity and agreement to be a great benefit for both companys.

    The recent sharp drop in the Canadian Dollar was also a driving factor in the completion of this deal, as Canadian assets have become much more attractive at discounted rates in US Dollar terms. Easton’s US partners have shown great interest in diversifying through Joint venture operations in Canada centered on patient acquisition as well as transdermal medication delivery and associated product launch. Details on these initiatives in both US and Canadian markets should be ready for disclosure by early next week. The two Medicated Markets Califiornia Master grower License numbers are #B8377788, and #330471333. More pictures of current mother plants used for cloning, dispensary cash receipts as well as grow location addresses will be available at https://twitter.com/medimarkets in the coming days.

    Medical cannabis is commonly used to self-treat severe pain associated with Cancer, arthritis, musculoskeletal pain and other ailments. As of June 2014, estimates from the office of Information Commissioner of Canada list “severe arthritis” as the main reason 65% of Canadians are possessing marijuana for medicinal purposes. Proposed initiatives hope to eventually allow the transdermal delivery of medicinal marijuana to a patient’s area of pain, without having to inhale through the lungs. Currently McGill University, McMaster University, and University of Guelph have ongoing research projects into Medical Marijuana in Canada.

    The Medical Marijuana Movement in North America started in California, which was the first state to establish a medical marijuana program, enacted by Proposition 215 in 1996 and Senate Bill 420 in 2003. Prop. 215, also known as the Compassionate Use Act, was approved by an initiative with a 55% majority, allowing people with cancer, AIDS and other chronic illnesses the right to grow or obtain marijuana for medical purposes when recommended by a doctor. SB 420, or the Medical Marijuana Protection Act, was signed into law by Governor Gray Davis and established an identification card system for medical marijuana patients. Marijuana advocates are hopeful that if they can get a legalization measure on the ballot in California in 2016, it will pass and federal reform will follow shortly afterwards.

    About Easton Pharmaceuticals

    Related Quotes

    • Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs to treat cancer and other conditions that are in various stages of development with 3 of its OTC products to soon be ready for marketing and sale. Easton has completed an acquisition that grants a 40% ownership interest in Medicated Markets International LLC; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada, located in Ontario, Canada which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

    0 260

    Organigram Provides Shareholder Update

    MONCTON, NEW BRUNSWICK–(Marketwired – Jan 20, 2015) – OrganiGram Holdings Inc.(TSX VENTURE:OGI)(OGRMF) (the “Company“) is pleased to provide an update to shareholders while reviewing milestones of 2014 and looking at the growth and goals of 2015.

    Since the inception of Organigram in April 2014, the Company has been growing and developing at a very fast pace. Through this growth, there have been some tremendous achievements, which include receiving our organic certification, producing our first crops, listing of shares on the TSX Venture and completing three phases of construction. Organigram is excited to capitalize on these achievements and execute on the our business plan

    Moving forward, our shareholders, patients and partners will begin to see the results from the foundation laid in 2014. To date, the company has been extremely focused on expanding the production facility while, at the same time, working to increase production levels. These efforts will begin to provide significant product to the market in March of this year. Thereafter, the utilization of our existing rooms and rooms under construction will ensure that Organigram is poised to meet our financial goals in 2015.

    Organigram would like to take this opportunity to congratulate Trauma Healing Centers on the opening of their first clinic, in Halifax, NS. Organigram is proud to be partnered with Trauma Healing Centers on research initiatives to assist our Veterans and others suffering with PTSD.

    Organigram’s CEO, Denis Arsenault states, “Over the past few months, Organigram has moved into a “best in class” manufacturing facility. Our processes and systems have been developed to a point where we produce high quality products, in an organic form, which has and will continue to exceed the requirements of our clients. While we continue to evolve and improve, our facility will begin to supply the market with an established source of product on a consistent basis. We have a superior management team in place that is not only focused on supply but also quality, efficiency and product development. The results of our efforts will not only be very profitable for the company and shareholders but most importantly will provide a rapidly increasing client base with a medicinal product that assists in a much-improved quality of life for many. The developments of the next few weeks and months will be both exciting and fruitful for our company.”

    About Organigram Holdings Inc.

    Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

    On behalf of the board of directors,

    Denis Arsenault, Director and CEO

    Organigram Holdings Inc.

    For further information please visitwww.organigram.ca.

    The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:
    Brett Allan
    Dir. Of Investor Relations
    OrganiGram Holdings Inc.
    (416) 907-4148